81
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Brain mr perfusion imaging in humans : Advantages of high-molarity gadolinium chelates

, , &
Pages 555-559 | Published online: 09 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Frederik L. Giesel, Amit Mehndiratta, Frank Risse, Maria Rius, Christian M. Zechmann, Hendrik von Tengg-Kobligk, Lars Gerigk, Hans-Ulrich Kauczor, Maria Politi, Marco Essig, Paul D. Griffiths & Iain D. Wilkinson. (2009) Intraindividual Comparison between Gadopentetate Dimeglumine and Gadobutrol for Magnetic Resonance Perfusion in Normal Brain and Intracranial Tumors at 3 Tesla. Acta Radiologica 50:5, pages 521-530.
Read now
P. D. Griffiths, H. Pandya, I. D. Wilkinson & N. Hoggard. (2006) Sequential Dynamic Gadolinium Magnetic Resonance Perfusion-Weighted Imaging: Effects on Transit Time and Cerebral Blood Volume Measurements. Acta Radiologica 47:10, pages 1079-1084.
Read now
M. E011011011011011011ssig, F. W011011011011011011enz, R. S011011011011011011choldei, R. B011011011011011011rüning, C. B011011011011011011erchtenbreiter, M. M011011011011011011eurer & M. V. K011011011011011011nopp. (2002) Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas: Effect of contrast medium extravasation. Acta Radiologica 43:4, pages 354-359.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.